BNP Paribas Asset Management
CRSP icon

BNP Paribas Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

BNP Paribas Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.3K Sell
1,270
-244
-16% -$12.9K ﹤0.01% 1654
2026
Q1 		$72K Buy
1,514
+396
+35% +$20.9K ﹤0.01% 1619
2025
Q4 		$59K Buy
1,118
+322
+40% +$19.3K ﹤0.01% 1609
2025
Q3 		$52K Buy
796
+35
+5% +$2.01K ﹤0.01% 1045
2025
Q2 		$37K Buy
+761
New +$29.4K ﹤0.01% 1242

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BNP Paribas Asset Management's CRSP Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 16% in Q2 2026, selling an estimated $12.9K and leaving 1,270 shares worth $69.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1654.

BNP Paribas Asset Management first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $72K in Q1 2026. 407 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • BNP Paribas Asset Management held 1,270 shares of CRISPR Therapeutics worth $69.3K as of Q2 2026.
  • BNP Paribas Asset Management sold 244 CRISPR Therapeutics shares in Q2 2026, an estimated $12.9K.
  • CRISPR Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1654 holding.
  • BNP Paribas Asset Management first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's CRISPR Therapeutics position peaked at $72K in Q1 2026.
  • 407 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.